Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.